Review





Similar Products

mybl2 ha hg14536 cy plasmids  (Sino Biological)
93
Sino Biological mybl2 ha hg14536 cy plasmids
Mybl2 Ha Hg14536 Cy Plasmids, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mybl2 ha hg14536 cy plasmids/product/Sino Biological
Average 93 stars, based on 1 article reviews
mybl2 ha hg14536 cy plasmids - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
mybl2  (Proteintech)
93
Proteintech mybl2
(A) Chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) was performed using an anti-RNAPII (8WG16) antibody to evaluate recruitment of RNA polymerase II to the RRM2 promoter, with or without osimertinib (Osi) treatment. Relative enrichment was normalized to the ACTB promoter. (B) ChIP-qPCR using HA-tagged <t>MYBL2-overexpressing</t> cell lines was conducted to assess MYBL2 binding to the RRM2 promoter. Promoter occupancy is shown relative to input. Data are presented as mean ± s.e.m. (n = 3). ***p < 0.001. (C) RRM2 mRNA expression was quantified by RT-qPCR in PC-9 and HCC827 cells following EGFR knockdown using siRNA. Transcript levels were normalized to GAPDH. (D) The impact of EGFR knockdown on MYBL2 recruitment to the RRM2 promoter was evaluated by ChIP-qPCR in HA-MYBL2-expressing cells transfected with control or EGFR siRNA. Promoter enrichment was normalized to input. Data are shown as mean ± s.e.m. (n = 3). ***p < 0.001. All data are representative of at least three independent experiments.
Mybl2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mybl2/product/Proteintech
Average 93 stars, based on 1 article reviews
mybl2 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
anti mybl2  (Proteintech)
93
Proteintech anti mybl2
(A) Chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) was performed using an anti-RNAPII (8WG16) antibody to evaluate recruitment of RNA polymerase II to the RRM2 promoter, with or without osimertinib (Osi) treatment. Relative enrichment was normalized to the ACTB promoter. (B) ChIP-qPCR using HA-tagged <t>MYBL2-overexpressing</t> cell lines was conducted to assess MYBL2 binding to the RRM2 promoter. Promoter occupancy is shown relative to input. Data are presented as mean ± s.e.m. (n = 3). ***p < 0.001. (C) RRM2 mRNA expression was quantified by RT-qPCR in PC-9 and HCC827 cells following EGFR knockdown using siRNA. Transcript levels were normalized to GAPDH. (D) The impact of EGFR knockdown on MYBL2 recruitment to the RRM2 promoter was evaluated by ChIP-qPCR in HA-MYBL2-expressing cells transfected with control or EGFR siRNA. Promoter enrichment was normalized to input. Data are shown as mean ± s.e.m. (n = 3). ***p < 0.001. All data are representative of at least three independent experiments.
Anti Mybl2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mybl2/product/Proteintech
Average 93 stars, based on 1 article reviews
anti mybl2 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

Image Search Results


(A) Chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) was performed using an anti-RNAPII (8WG16) antibody to evaluate recruitment of RNA polymerase II to the RRM2 promoter, with or without osimertinib (Osi) treatment. Relative enrichment was normalized to the ACTB promoter. (B) ChIP-qPCR using HA-tagged MYBL2-overexpressing cell lines was conducted to assess MYBL2 binding to the RRM2 promoter. Promoter occupancy is shown relative to input. Data are presented as mean ± s.e.m. (n = 3). ***p < 0.001. (C) RRM2 mRNA expression was quantified by RT-qPCR in PC-9 and HCC827 cells following EGFR knockdown using siRNA. Transcript levels were normalized to GAPDH. (D) The impact of EGFR knockdown on MYBL2 recruitment to the RRM2 promoter was evaluated by ChIP-qPCR in HA-MYBL2-expressing cells transfected with control or EGFR siRNA. Promoter enrichment was normalized to input. Data are shown as mean ± s.e.m. (n = 3). ***p < 0.001. All data are representative of at least three independent experiments.

Journal: bioRxiv

Article Title: Adaptive regulation of dNTP homeostasis confers osimertinib resistance in EGFR mutant non-small cell lung carcinoma

doi: 10.64898/2025.12.24.696437

Figure Lengend Snippet: (A) Chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) was performed using an anti-RNAPII (8WG16) antibody to evaluate recruitment of RNA polymerase II to the RRM2 promoter, with or without osimertinib (Osi) treatment. Relative enrichment was normalized to the ACTB promoter. (B) ChIP-qPCR using HA-tagged MYBL2-overexpressing cell lines was conducted to assess MYBL2 binding to the RRM2 promoter. Promoter occupancy is shown relative to input. Data are presented as mean ± s.e.m. (n = 3). ***p < 0.001. (C) RRM2 mRNA expression was quantified by RT-qPCR in PC-9 and HCC827 cells following EGFR knockdown using siRNA. Transcript levels were normalized to GAPDH. (D) The impact of EGFR knockdown on MYBL2 recruitment to the RRM2 promoter was evaluated by ChIP-qPCR in HA-MYBL2-expressing cells transfected with control or EGFR siRNA. Promoter enrichment was normalized to input. Data are shown as mean ± s.e.m. (n = 3). ***p < 0.001. All data are representative of at least three independent experiments.

Article Snippet: RRM1 (#10526-1-AP), RRM2 (11661-1-AP), RRM2B (#18005-1-AP), CHK1 (#25887-1-AP), CHK2 (#13954-1-AP), EGFR (#66455-1-Ig), beta Actin (#20536-1-AP), HA tag (#51064-2-AP), Histone H3 (#17168-1-AP), GAPDH (#60004-1-Ig), POLD1(#15646-1-AP), POLH (#28133-1-AP), MYBL2 (#18896-1-AP) and TNNT3 (#19729-1-AP) were purchased from Proteintech.

Techniques: Chromatin Immunoprecipitation, ChIP-qPCR, Binding Assay, Expressing, Quantitative RT-PCR, Knockdown, Transfection, Control

Stepwise drug escalation assay to generate resistance to combined treatment with cell cycle checkpoint inhibitors (PV1019 or LY2606368) and osimertinib in (A) PC-9 and (B) HCC827 and cells. Cells were exposed to increasing concentrations of osimertinib, starting at 10 nM and escalating to 1000 nM over several weeks. At each step, proliferating cells were expanded until resistance was confirmed by sustained growth in 1000 nM osimertinib, assessed via trypan blue exclusion assay. (C) Tumor growth rates of HCC827 xenografts treated with DMSO (vehicle control, n=8), osimertinib (n=8), LY2606368 at 1 mg/kg or 3 mg/kg (n=5 each), or a combination of osimertinib with LY2606368 at each dose (n=7 and n=9, respectively). Tumor volumes were measured twice weekly and are presented as mean ± SEM. Statistical significance was determined using Student’s t -test. (D) Relative mRNA expression levels of RRM2B, RRM2, MYBL2, TNNT3, and CHK1 in tumor tissues following treatment with DMSO or osimertinib, as measured by quantitative RT-PCR.

Journal: bioRxiv

Article Title: Adaptive regulation of dNTP homeostasis confers osimertinib resistance in EGFR mutant non-small cell lung carcinoma

doi: 10.64898/2025.12.24.696437

Figure Lengend Snippet: Stepwise drug escalation assay to generate resistance to combined treatment with cell cycle checkpoint inhibitors (PV1019 or LY2606368) and osimertinib in (A) PC-9 and (B) HCC827 and cells. Cells were exposed to increasing concentrations of osimertinib, starting at 10 nM and escalating to 1000 nM over several weeks. At each step, proliferating cells were expanded until resistance was confirmed by sustained growth in 1000 nM osimertinib, assessed via trypan blue exclusion assay. (C) Tumor growth rates of HCC827 xenografts treated with DMSO (vehicle control, n=8), osimertinib (n=8), LY2606368 at 1 mg/kg or 3 mg/kg (n=5 each), or a combination of osimertinib with LY2606368 at each dose (n=7 and n=9, respectively). Tumor volumes were measured twice weekly and are presented as mean ± SEM. Statistical significance was determined using Student’s t -test. (D) Relative mRNA expression levels of RRM2B, RRM2, MYBL2, TNNT3, and CHK1 in tumor tissues following treatment with DMSO or osimertinib, as measured by quantitative RT-PCR.

Article Snippet: RRM1 (#10526-1-AP), RRM2 (11661-1-AP), RRM2B (#18005-1-AP), CHK1 (#25887-1-AP), CHK2 (#13954-1-AP), EGFR (#66455-1-Ig), beta Actin (#20536-1-AP), HA tag (#51064-2-AP), Histone H3 (#17168-1-AP), GAPDH (#60004-1-Ig), POLD1(#15646-1-AP), POLH (#28133-1-AP), MYBL2 (#18896-1-AP) and TNNT3 (#19729-1-AP) were purchased from Proteintech.

Techniques: Trypan Blue Exclusion Assay, Control, Expressing, Quantitative RT-PCR